Efficacy assessment of modern regimens of preventive antituberculosis therapy in patients basically treated with TNF-α inhibitors

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Background. Biological agents, especially anti-tumor necrosis factor blocking agents, frequently are used to treat autoimmune inflammatory rheumatic diseases. Due to their negative impact on immune system and high risk of reactivation of latent tuberculosis infection all the patients must be well examined before initiation of an anti-tumor necrosis factor therapy (ATNFT).

Purposes and tasks. An estimation of efficiency of preventive anti-tuberculosis therapy (PATT) with patients undergoing ATNFT.

Methods and materials. In the research took part 128 patients, suffering from different inflammatory rheumatic diseases, whom was planned anti-tumor necrosis factor therapy. In 62 cases were found the indications for prescription PATT for 4 weeks before initiation of biological therapy and from 8 to 20 weeks after.

Results. An active tuberculosis has been developed in 8 cases, the process was similar to tuberculosis and human immunodeficiency virus. The factors of risk were the prescription adalimumab and infliximab, impaired glucose tolerance, diabetes type 2 and drunkenness abuse.

Conclusion. The existing preventive anti-tuberculosis therapy is not able to preclude the development of tuberculosis in all cases and needs to be optimized.


Full Text

Restricted Access

About the authors

Aleksei O. Barnaulov

Mechnikov North-West State Medical University

Author for correspondence.
Email: zhvitalik@list.ru

Russian Federation, Saint Petersburg

Assistant, Dept. of Phthisiopulmonology and Thoracic Surgery

Irina A. Rasmagina

Mechnikov North-West State Medical University

Email: aleksei.barnaulov@szgmu.ru

Russian Federation, Saint Petersburg

6th year Student

Marina N. Kondakova

Mechnikov North-West State Medical University

Email: aleksei.barnaulov@szgmu.ru

Russian Federation, Saint Petersburg

Dr. Med. Sci., Professor, Dept. of Phthisiopulmonology and Thoracic Surgery

Vitaliy V. Khabirov

Mechnikov North-West State Medical University

Email: aleksei.barnaulov@szgmu.ru

Russian Federation, Saint Petersburg

Laboratory Assistant, Dept. of Phthisiopulmonology and Thoracic Surgery

Elena B. Lelekova

Mechnikov North-West State Medical University

Email: aleksei.barnaulov@szgmu.ru

Russian Federation, Saint Petersburg

Laboratory Assistant, Dept. of Phthisiopulmonology and Thoracic Surgery

References

  1. Балабанова Р.М., Дубинина Т.В., Эрдес Ш.Ф. Динамика заболеваемости ревматическими заболеваниями взрослого населения России за 2010–2014 гг. // Научно-практическая ревматология. – 2016. – Т. 54. – № 3. – С. 266–270. [Balabanova RM, Dubinina TV, Erdes SF. Trends in the incidence of rheumatic diseases in the adult population of Russia over 2010-2014. Rheumatology Science and Practice. 2016;54(3):266-270. (In Russ.)]. doi: 10.14412/1995-4484-2016-266-70.
  2. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Рекомендации EULAR по лечению ревматоидного артрита-2013: общая характеристика и дискуссионные проблемы // Научно-практическая ревматология. – 2013. – Т. 51. – № 6. – С. 609–622. [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis-2013: general characteristics and disputable problems. Rheumatology Science and Practice. 2013;51(6): 609-622. (In Russ.)]. doi: 10.14412/1995-4484-2013-609-22.
  3. Козлов Р.С., Насонов Е.Л., Якушин С.Б. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден значит вооружен // Клиническая микробиология и антимикробная химиотерапия. – 2006. – Т. 8. – № 4. – С. 314–324. [Kozlov RS, Nasonov EL, Yakushin SB. Infectious complications of the anti-TNF therapy: “Praemonitus, praemunitus”. Clin Microbiol and Antimicrobal Chemother. 2006;8(4):314-324. (In Russ.)]
  4. Wallis RS, Broder MS, Wong JY, et al. Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists. Clin Infect Dis. 2004;38(9):1261-1265. doi: 10.1086/383317.
  5. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60(7):1884-1894. https://doi.org/10.1002/art.24632.
  6. Beglinger C, Dudler J, Mottet C. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly. 2007;137(43-44):620-622.
  7. Диагностика туберкулезной инфекции при планировании и проведении терапии блокаторами ФНОα у больных ревматическими заболеваниями: Пособие для врачей / под ред. Е.Л. Насонова, М.И. Перельман. – М., 2008. – 40 с. [Diagnostika tuberkuleznoy infektsii pri planirovanii i provedenii terapii blokatorami FNOα u bol’nykh revmaticheskimi zabolevaniyami: Posobie dlya vrachey. Ed. by E.L. Nasonov and M.A. Perel’man. Moscow; 2008. 40 p. (In Russ.)]
  8. Белов Б.С., Борисов С.Е., Лукина Г.В., и др. Рекомендации по скринингу и мониторингу туберкулезной инфекции у больных, получающих генно-инженерные биологические препараты. – М., 2010. – С.11–14. [Belov BS, Borisov SE, Lukina GV, et al. Rekomendatsii po skriningu i monitoringu tuberkuleznoy infektsii u bol’nykh, poluchayushchikh genno-inzhenernye biologicheskie preparaty. Moscow; 2010. P. 11-14 (In Russ.)]. Доступен по: www.rheumatolog.ru/files/natrec21/.pdf.

Statistics

Views

Abstract - 53

PDF (Russian) - 1

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Barnaulov A.O., Rasmagina I.A., Kondakova M.N., Khabirov V.V., Lelekova E.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies